Holen Sie sich die Stockscreener-App
39.96
2.94%
-1.21
Handel nachbörslich:
39.70
-0.26
-0.65%
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - The Motley Fool
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - The Motley Fool
Published on: 2026-03-13 13:04:33 - baoquankhu1.vn
Aug Big Picture: What is the cash position of Vera Therapeutics Inc2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Vera Therapeutics urges expanded innovation in global kidney health on World Kidney Day - Traders Union
Quarterly Trades: Can Vera Therapeutics Inc deliver consistent EPS growth2026 Investor Takeaways & Community Shared Stock Ideas - baoquankhu1.vn
Vera Therapeutics (NASDAQ:VERA) Upgraded to Outperform at Wolfe Research - MarketBeat
How (VERA) Movements Inform Risk Allocation Models - Stock Traders Daily
Wolfe Research upgrades Vera Therapeutics stock rating on valuation By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Trading Up 10.2%What's Next? - MarketBeat
Vera Therapeutics’ Atacicept Gains FDA Priority, Stock Soars - StocksToTrade
Vera Therapeutics stock rating reaffirmed at Buy by BofA Securities - Investing.com Canada
Vera Therapeutics Adds Christopher Hite to Board - TipRanks
Vera Therapeutics Appoints New Board Member - Intellectia AI
Can Vera Therapeutics Inc. stock deliver surprise earnings beat2026 EndofYear Setup & Weekly Return Optimization Plans - Naître et grandir
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Six new Vera Therapeutics hires receive 4-year stock awards - Stock Titan
Vanguard Group Inc. Has $92.72 Million Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics Appoints Christopher Hite to Board of Directors - Sahm
Vera Therapeutics adds Christopher Hite to board of directors By Investing.com - Investing.com Canada
Vera Therapeutics adds Christopher Hite to board of directors - Investing.com
Vera Therapeutics appoints Christopher Hite to board of directors - marketscreener.com
Vera Therapeutics Appoints Christopher Hite To Board Of Directors - TradingView
Royalty Pharma vice chair joins Vera board before potential IgA drug launch - Stock Titan
Q1 EPS Estimates for Vera Therapeutics Cut by HC Wainwright - MarketBeat
Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026 - Intellectia AI
Vera Therapeutics, Inc. (VERA) Stock Analysis: 94.88% Potential Upside Signals Compelling Opportunity - DirectorsTalk Interviews
Insider Sells $90,298 in Vera Therapeutics Stock - National Today
HC Wainwright Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price - MarketBeat
VERA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HC Wainwright & Co. Raises Price Target on Vera Therapeutics (VE - GuruFocus
Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA) - simplywall.st
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Key facts: Vera Therapeutics submits atacicept BLA; posts $299.6M loss - TradingView
Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating - marketscreener.com
Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)? - Yahoo Finance
Vera Therapeutics, Inc. SEC 10-K Report - TradingView
VERA: Net loss widened to $299.6M as R&D and G&A spending surged ahead of potential atacicept approval - TradingView
Atacicept progress puts Vera Therapeutics (NASDAQ: VERA) at key FDA milestone - Stock Titan
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vera Therapeutics Raises $261M in Public Offering at $42.50 per Share - Intellectia AI
VERA: FDA priority review and strong cash reserves set the stage for atacicept's 2026 launch - TradingView
BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55 - TradingView
Vera Therapeutics (VERA) widens 2025 loss as atacicept wins FDA priority review - Stock Titan
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) SVP Sells $130,851.66 in Stock - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Insider Laurence Matthew Skelton Sells 1,582 Shares - MarketBeat
Insider Selling: Vera Therapeutics (NASDAQ:VERA) Insider Sells 2,187 Shares of Stock - MarketBeat
Insider Selling: Vera Therapeutics (NASDAQ:VERA) COO Sells 2,579 Shares of Stock - MarketBeat
Vera Therapeutics (VERA) CEO executes 16,925-share tax sell-to-cover trade - Stock Titan
Vera Therapeutics (VERA) CCO sells 1,582 shares in RSU tax sale - Stock Titan
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Broker files Rule 144 to sell 1,800 VERA shares (NASDAQ: VERA) - Stock Titan
Morgan Stanley to sell 2,600 VERA shares (NASDAQ: VERA) under Rule 144 - Stock Titan
VERA (NASDAQ: VERA) notice of 5,700-share sale via Form 144 - Stock Titan
Morgan Stanley Smith Barney reports sale of 2,500 VERA shares (VERA) - Stock Titan
[144] Vera Therapeutics, Inc. SEC Filing - Stock Titan
VERA (NASDAQ: VERA) files Rule 144 sale notice for 16,600 shares - Stock Titan
Options Flow: How cyclical is Vera Therapeutics Incs revenue streamBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Vera Therapeutics (VERA) Valuation After Atacicept Phase 3 Success And Analyst Downgrade - Sahm
Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade) - Seeking Alpha
Published on: 2026-02-20 18:05:40 - mfd.ru
Analysts bullish on Vera Therapeutics (VERA) amid new commercial chief appointment - MSN
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):